{"id":22091,"date":"2025-03-01T18:42:16","date_gmt":"2025-03-01T05:42:16","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=22091"},"modified":"2025-05-07T16:57:15","modified_gmt":"2025-05-07T03:57:15","slug":"take-a-look-at-our-cll-diagnosis-treatment-pathway-in-nz-here-cll-care-pathway-2023","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=22091","title":{"rendered":"Take a look at our CLL DIAGNOSIS &#038; TREATMENT PATHWAY IN NZ"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p>This <a href=\"https:\/\/clladvocates.nz\/wp-content\/uploads\/2023\/05\/CLL_Treatment_Pathway_2023-1.jpg\" target=\"_blank\" rel=\"noopener\">flow chart<\/a> outlines the diagnosis and treatment pathway for <strong>Chronic Lymphocytic Leukaemia (CLL)<\/strong> in New Zealand, including the staging process, risk assessment, and available treatment options.<\/p>\n<h3><strong>Key Points:<\/strong><\/h3>\n<ul>\n<li><strong>Diagnosis &amp; Staging:<\/strong> Initial testing includes full blood count (FBC), immunophenotyping, and cytogenetic testing. Staging methods include <strong>Binet (used in NZ, UK, and Europe)<\/strong> and <strong>RAI (used in the US)<\/strong> to assess disease extent.<\/li>\n<li><strong>Treatment Pathways:<\/strong>\n<ul>\n<li><strong>First-Line Treatments:<\/strong> Options vary based on patient fitness, including chemo-immunotherapy (FCR, Bendamustine-Rituximab) and targeted therapies like <strong>Ibrutinib, Idelalisib, and Venetoclax<\/strong> for certain genetic mutations.<\/li>\n<li><strong>Second-Line Treatment:<\/strong> Requires a different approach from the first-line therapy and includes targeted therapies, stem cell transplantation, radiotherapy, and corticosteroids.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Watch &amp; Wait:<\/strong> For patients with stable disease, monitoring includes regular blood tests, skin cancer tests, physical exams, psychosocial support, and fatigue management.<\/li>\n<li><strong>Clinical Trials:<\/strong> Some <strong>new treatments<\/strong> being explored include <strong>CAR T-cell therapy, cyclin-dependent kinase inhibitors, histone deacetylase inhibitors, and second-generation BCR\/BCL-2 inhibitors.<\/strong><\/li>\n<li><strong>Funding Status:<\/strong> Certain treatments are <strong>funded in NZ<\/strong>, while others remain <strong>unfunded<\/strong>.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; This flow chart outlines the diagnosis and treatment pathway for Chronic Lymphocytic Leukaemia (CLL) in New Zealand, including the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":22277,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17],"tags":[79,82,94,105,131,132,142],"class_list":["post-22091","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","tag-sam-neil-blood-cancer-pharmac","tag-rachel-smalley","tag-zanubrutinib-sonrotoclax","tag-dr-malcolm-mulholland","tag-christopher-luxon","tag-shane-reti","tag-sarah-fitt-pharmac"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2025\/03\/CLL_snippet.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/22091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22091"}],"version-history":[{"count":7,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/22091\/revisions"}],"predecessor-version":[{"id":22282,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/22091\/revisions\/22282"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/22277"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}